April 23, 2021– Billions of dollars in Medicare payment cuts to hospitals participating in the 340B drug pricing program have harmed the health care safety net since they first went into effect more than three years ago. 340B hospitals and their supporters are asking the Biden administration and the 117th Congress to reverse those cuts and restore equity to Medicare Part B drug … [Read more...]
Research Highlights the Toll of Drug Maker Attacks on 340B, Shows How Hospitals Use Their Savings to Care for Patients
March 23, 2021– Newly released research demonstrates how patients benefit from the 340B drug pricing program in the form of expanded access and improved health outcomes. But there is growing evidence that the actions of six drug companies to cut off 340B discounts for certain drugs is sapping needed resources during the continued COVID-19 pandemic. 340B Health’s annual … [Read more...]
New Data May Convince Congress To Close 340B Loophole
March 18, 2021– One of the quieter debates around the 340B drug pricing program is percolating on Capitol Hill as lawmakers consider whether to plug a loophole in the law that costs rural hospitals much-needed resources. Members of Congress from both parties are looking to pass legislation to make a change on this issue. And a recent study in the prestigious journal Health … [Read more...]
340B Providers Contemplate the Challenges Met and Prepare for the Ones Ahead
By Maureen Testoni March 11, 2021– In this pandemic-focused world we all find ourselves in, it seems only fitting that one of my highlights of this past month was getting the chance to meet Fauci. No, I’m not talking about the esteemed Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, who has become a household name over the past … [Read more...]
Drug Giant’s Revenues Soar While 340B Cuts Sting
February 10, 2021– While hospitals across the country have been struggling to stay afloat and serve the health needs of a nation during a historic pandemic, one of the largest drug companies in the U.S. has been boosting its already huge profits by denying safety-net providers the drug discounts that the 340B drug pricing program requires. Two new reports show that as drug … [Read more...]
340B Hospitals Are Key to the Pursuit of Health Equity
February 8, 2021– A global pandemic, an economic recession, and social strife in communities across the nation have cast a bright light on the deep racial and ethnic inequities in the U.S., starting a national dialogue that aspires to put us on a path toward real change. President Biden and his administration have made pursuing equity in health care and many other areas of our … [Read more...]
Senate Report Blasts Insulin Makers for High Prices
January 21, 2021– A new, bipartisan report from a key congressional committee is sharply critical of the three major drug manufacturers that sell insulin in the U.S. The companies – Eli Lilly, Novo Nordisk, and Sanofi – already have been all over the news recently for their pricing behavior. They also are the ringleaders of a group of drug companies that are circumventing … [Read more...]